JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)

计划入组 25 人 · 首次发布于 2024 年 9 月 13 日

Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)

计划入组 40 人 · 首次发布于 2021 年 11 月 15 日

ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme

计划入组 100 人 · 首次发布于 2020 年 10 月 14 日

NC-3

CAR T-cell therapy (glioblastoma multiforme)

Therapeutic Glioblastoma Multiforme Vaccine(Amal Therapeutics)

GEM PHARMACEUTICALS

India

ABM Therapeutics Corporation

United States

HBM Pharma s.r.o.

Slovakia

Alpha Tau Receives FDA TAP Acceptance to Expedite Alpha DaRT for Recurrent Glioblastoma

Genenta Science's Temferon Receives Approval for Phase 1 Trial in Metastatic Renal Cell Carcinoma

FDA Approves Novocure's Lighter, More Flexible Transducer Arrays for Optune Gio in Glioblastoma